Ram Mukunda - 21 Mar 2022 Form 4 Insider Report for India Globalization Capital, Inc. (IGC)

Role
CEO, Director
Signature
/s/ Ram Mukunda
Issuer symbol
IGC
Transactions as of
21 Mar 2022
Transactions value $
$0
Form type
4
Filing time
28 Jun 2022, 19:08:26 UTC
Previous filing
23 Dec 2021
Next filing
12 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IGC Common Stock Options Exercise $0 +333,334 +15% $0 2,508,094 21 Mar 2022 Direct F1
transaction IGC Common Stock Options Exercise $0 +600,000 +24% $0 3,108,094 31 May 2022 Direct F2
transaction IGC Common Stock Options Exercise $0 +200,000 +6.4% $0 3,308,094 01 Jun 2022 Direct F2
transaction IGC Common Stock Options Exercise $0 +16,667 +2.3% $0 744,084 21 Mar 2022 BY SPOUSE F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IGC Restricted Stock Units Options Exercise $0 -333,334 -7.9% $0 3,866,666 21 Mar 2022 Common Stock 333,334 $0 Direct F1
transaction IGC Restricted Stock Units Options Exercise $0 -600,000 -16% $0 3,266,666 31 May 2022 Common Stock 600,000 $0 Direct F2
transaction IGC Restricted Stock Units Options Exercise $0 -200,000 -6.1% $0 3,066,666 01 Jun 2022 Common Stock 200,000 $0 Direct F2
transaction IGC Restricted Stock Units Options Exercise $0 -16,667 -33% $0 33,333 21 Mar 2022 Common Stock 16,667 $0 BY SPOUSE F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 19, 2021, the Reporting Person was granted RSUs subject to vesting equally over three years starting on March 31, 2022.
F2 On December 20, 2021, the Reporting Person was granted RSUs subject to vesting according to specific milestones set by the Company's Board of Directors. The RSUs vest when milestones are achieved. On May 31 and June 1, 2022, two of the milestones related to our IGC-AD1 clinical trials were reached.